Marco Bocci

Marco Bocci


Marco is a highly accomplished C-suite executive (CBO/CEO), advisory board member, and qualified pharmacist. He is an expert in driving innovation, strategic growth, and operational excellence within the global biotechnology, MedTech, and pharmaceutical industries.

As an authentic leader with a passion for improving human health through innovation, Marco has a keen insight into emerging trends and technologies. His key strengths include providing strategic guidance and thought leadership as a trusted advisor to executive teams and boards, fostering cross-functional partnerships, and guiding companies through periods of transformation and growth. Marco excels in assembling and leading high-performing teams that exceed expectations in delivering organisational objectives.

He combines a proven track record in business development with expertise in project management, licensing, and negotiation to secure high-value partnership deals. Marco has a track record with over 120 closed deals and commercial licenses worth over $1 billion, including several orphan diseases licensing deals bringing much-needed products into the clinics. He also has extensive experience in the whole spectrum of drug development activities from early R&D through to manufacturing, clinical development, and commercialization.

Marco's deep understanding of business needs, opportunities, risks, and challenges allows him to influence strategy and guide decision-making effectively. With remarkable tenacity and skillful efforts, Marco has devised and implemented commercial strategies that have led to significant financial results and increased the long-term, sustainable success of the companies in which he worked, playing an instrumental role in elevating them to become the industry’s recognized new gold standards in the sector.

Marco holds a Doctor of Pharmacy (DPharm) degree from the University of Siena, and a PhD from the University of Cambridge, UK. He also serves as an advisory board member of the Rethink! Foundation.